|
|
|
|
|
|
Cell and gene therapy, along with advanced analytics, remain at the forefront of today’s most complex therapeutic programs, and knowing where to find the right expertise has never been more critical. That’s why the Outsourced Pharma Capacity Update has evolved into the Outsourced Pharma Capabilities Update (OPCU) — a series designed to go beyond capacity and highlight what truly sets partners apart: the technologies, experience, and specialized capabilities CDMOs bring to your programs.
Across these sessions, you’ll gain valuable insights into the most critical stages of development — and how the right partners can accelerate timelines, enhance analytical rigor, and de-risk scale-up for advanced therapy assets.
Tune in each month to our expanded PARTNER WEEK, now organized by capability area, making it easier than ever to explore targeted expertise in cell and gene therapy and analytics — exactly when you need it.
Recent Sessions Available On-Demand
Large Molecule – 3/10/2026, AM Session
Fill / Finish – 3/10/2026, PM Session
Upcoming OPCU Topics & Times
Small Molecule Drug Product | 4/21/2026, AM Session
Fill/Finish | 4/22/2026, PM Session
Access more on-demand OPCU recordings and upcoming sessions here.
|
|
|
|
|
|
Pace Life Sciences
|
A CDMO leader highlights two decades of growth, showcasing analytical strength, manufacturing, regulatory support, and integrated services that speed drug development.
|
|
Request Information
|
|
Pace® Life Sciences
|
|
|
|
Solvias
|
A biotech leader emphasizes end‑to‑end analytical capabilities from development to commercialization, with expertise in biologics, gene therapies, quality testing, and regulatory solutions.
|
|
Request Information
|
|
Solvias
|
|
|
|
Catalent
|
A biologics analytics leader showcases development, testing, and characterization capabilities, emphasizing quality, regulatory compliance, and integrated support from discovery to commercialization.
|
|
Request Information
|
|
Catalent
|
|
|
|
Recipharm Advanced Bio
|
A lifecycle‑based analytical framework supporting release testing, stability studies, and product characterization to boost regulatory readiness, cut variability, and speed development.
|
|
Request Information
|
|
Recipharm Advanced Bio
|
|
|
|
Minaris
|
Access integrated biosafety testing, viral clearance, product characterization, and GMP analytics that deliver regulatory‑ready data and speed biologic and cell and gene therapy development.
|
|
Request Information
|
|
Minaris
|
|
|
|
|
|
Minaris
|
A global CDMO specializing in cell and gene therapies, offering end-to-end development, manufacturing, and testing services with over 25 years of expertise and personalized client support.
|
|
Request Information
|
|
Minaris
|
|
|
|
Lonza
|
A global CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through manufacturing.
|
|
Request Information
|
|
Lonza
|
|
|
|
Landmark Bio
|
A translational CDMO approach integrates development, analytics, and GMP manufacturing to streamline cell and gene therapy advancement from early research through clinical production.
|
|
Request Information
|
|
Landmark Bio
|
|
|
|
Comprehensive Cell Solutions
|
An integrated draw‑to‑thaw CDMO model connecting donor sourcing, development, GMP manufacturing, and cryogenic storage to streamline workflows and strengthen quality control.
|
|
Request Information
|
|
Comprehensive Cell Solutions, A Business Unit of NYBC Enterprises
|
|
|
|
ElevateBio
|
Learn how to embed process development expertise early and continuously to eliminate knowledge gaps, reduce risk, and ensure consistent execution from transfer through manufacturing.
|
|
Request Information
|
|
ElevateBio
|
|
|
|
|
